Buy Anti-HRSV F/Fusion glycoprotein F0 Antibody (Am14) (Human, IgG1) for ELISA, IHC, WB

Anti-HRSV F/Fusion glycoprotein F0 Antibody (Am14)

Catalog #: RVV02801 Specific References (0) DATASHEET

Bioactivity for Anti-HRSV F/Fusion glycoprotein F0 Antibody (Am14) ?>

SEC-HPLC for Anti-HRSV F/Fusion glycoprotein F0 Antibody (Am14) ?>

Flow Cytometry for Anti-HRSV F/Fusion glycoprotein F0 Antibody (Am14) ?>

Host species: Human

Isotype: IgG1

Applications: ELISA, IHC, Neutralization, WB

Expression system: Mammalian Cells

Overview

Catalog No.

RVV02801

Expression system

Mammalian Cells

Species reactivity

HRSV-A

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Applications

ELISA, IHC, Neutralization, WB

Recommended Dilution

Application	Dilution
ELISA	1:4000-1:8000, IHC: 1:50-1:200, WB: 1:1000-1:5000

Target

F,Fusion glycoprotein F0

Concentration

1.48 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03420

Form

Liquid

Storage buffer

100 mM Pro-Ac, 20 mM Arg, pH 5.0

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Am14

Note

For research use only.

Data Image

SDS-PAGE

SDS PAGE for F / Fusion glycoprotein F0
Bioactivity

Detects F/Fusion glycoprotein F0 in indirect ELISAs.
SEC-HPLC

The purity of this product is >95% as determined by SEC-HPLC.
Bioactivity

Detects HRSV F/Fusion glycoprotein F0 Protein in indirect ELISA.
Flow Cytometry

The percentage of cells transfected with the rAAV5-RSV-F and rAAV5-RSV-Fm vaccines that expressed membrane-associated forms of the RSV F protein bound by D25, 4D7, or AM14 was determined (A, B). (n=3) Statistical significance was calculated via two-way ANOVA with Dunnett's multiple comparisons. P values were adjusted for multiple comparisons. **p < 0.01, ***p < 0.001.
Data sourced from citation (PMID: 39469716)
Bioactivity

The nanomolar affinities between each antigen and Nirsevimab, as well as AM14-1, confirm their correct conformations, reflecting their varying degrees of immunogenicity.The "pre-fusogenic" BR30 prepared according to the ResVax (Novavax) methodology (GenBank: QEI22738.1), was included for comparison purpose.Annotations:* : Indicates single-chain mutation variants. # : Denotes mutants containing S46G, S215P, and K465Q.
Data sourced from citation (PMID: 39874917)
Bioactivity

BLI profiles of BR38 (A), BR40 (B), and BR42 (C). Each column depicts interactions with Nirsevimab, D25, AM14-1, AM14-2, MPE8, and Palivizumab from top to bottom.
Data sourced from citation (PMID: 39874917)
Bioactivity

The table presents affinity coefficients of BR38, BR40, and BR42 with various mAbs. BR40 shows superior antigenicity, while BR42 demonstrates comparable performance. BR38 exhibits inferior characteristics, notably decreased affinity to AM14.Annotations:# : Denotes mutants containing S46G, A149C-Y458C, S215P and K465Q.
Data sourced from citation (PMID: 39874917)
Bioactivity

Long-term stability evaluation. (A-B) Long-term stability assessment of vaccine bulk solutions stored at 4 ℃, evaluated using (A) Nirsevimab and (B) AM14-1. BR40 and BR42 maintained higher levels of neutralizing epitope activity compared to Standard-1 and BR38, indicating superior long-term stability.
Data sourced from citation (PMID: 39874917)

References

Datasheet

Document Download

Anti-HRSV F/Fusion glycoprotein F0 Antibody (Am14).pdf

$ 372

Product specifications

100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here